Fidelma L. Fitzpatrick

California Lead-Paint Abatement Litigation

Fidelma L. Fitzpatrick served as co-lead trial counsel in litigation that reached back nearly a century — addressing the promotion of residential lead paint and its continuing presence in older California housing, where it remained a live hazard inside occupied homes.

The Trial Record

A painted window can poison a child through nothing more than ordinary use. As the sash rises and the frame rubs, old pigment loosens onto the sill and the floor. Paint sold generations earlier remains an exposure source in the rooms where families still live.

Lead gave paint durability, opacity, and color, and manufacturers promoted it for residential interiors even as medical knowledge of childhood poisoning developed. The sale of lead paint eventually ended, but the material stayed behind — on windows, doors, kitchens, nurseries, and baseboards, sometimes sealed beneath later coats until age, friction, or renovation released it again.

Ten California cities and counties sued the former manufacturers over the lead paint remaining in their housing stock. The requested abatement program called for inspections, family education, stabilization of dangerous surfaces, and safe removal or containment.

The proof had to bridge eras — connecting industry promotion from one generation with exposure in another. Fitzpatrick and the team assembled advertisements, trade materials, scientific publications, internal documents, census and housing records, public-health evidence, and exposure evidence spanning decades, and placed the promotional record alongside the medical literature, the housing data, and the mechanics of paint deterioration inside a home. Her co-lead role joined that historical proof to the abatement work the cities and counties sought.

The evidence included National Lead's Dutch Boy promotions for interior use — among them a children's paint book depicting Dutch Boy White Lead in a playroom — and industry campaigns promoting white lead on residential windows and doors. The Court of Appeal later held that substantial evidence supported findings that manufacturers promoted lead paint for interior residential use with knowledge of the danger to children.

The trial court entered a $1.15 billion abatement judgment in 2014. In 2017, the Court of Appeal upheld the public-nuisance ruling and directed an abatement fund for pre-1951 homes; the California Supreme Court and the United States Supreme Court declined review. In 2019, after nearly two decades of litigation, the companies agreed to a $305 million settlement giving the participating jurisdictions flexible funds for inspections, education, treatment programs, and the safe removal or containment of lead hazards.

The settlement translated a record built from decades-old documents into work inside existing houses. Inspectors could test windows and doors, crews could stabilize or replace dangerous surfaces, and families could learn where lead dust traveled and how to reduce exposure. Evidence became abatement; abatement became protection for children not yet born when the paint was sold.

Essure Coordinated Litigation

Essure was designed as permanent birth control without abdominal surgery. Physicians placed flexible metal coils in the fallopian tubes, where tissue growth was intended to create a lasting barrier. Because the device was meant to remain in the body indefinitely, the litigation examined not only its design and warnings but what happened when a patient later reported a problem with an implanted coil.

Fitzpatrick led the plaintiffs' executive committee in coordinated California litigation concerning the device. The proceeding grew from fewer than one thousand cases to more than thirty thousand, with common discovery addressing design, testing, regulatory history, warnings, and the manufacturer's knowledge. Plaintiffs alleged that the device could migrate or perforate tissue and that removing it could require major surgery.

The proceeding ran on two connected levels of proof. Common discovery addressed the product and the manufacturer's knowledge; individual records traced each woman's placement, reported symptoms, imaging, and later medical care. Keeping those levels joined — as hundreds of files became tens of thousands — was the structural work of leadership.

The women themselves drove part of that structure. Patients who had encountered the device separately compared their experiences, organized, and pressed for reported patterns to be examined together. Their participation supplied the litigation with individual histories while the coordinated proceeding developed the shared design, testing, regulatory, and warning record.

In 2020, agreements totaling approximately $1.6 billion were reached to resolve about 90 percent of nearly 39,000 filed and unfiled Essure claims in the United States, with resolution discussions continuing for the remainder.

Complex Product-Liability Leadership

Fitzpatrick was appointed co-lead counsel in the American Medical Systems pelvic-mesh multidistrict litigation in 2012 and has tried pelvic-mesh bellwethers. She serves on the plaintiffs' executive committee in the Paragard IUD multidistrict litigation, serves as co-lead counsel in a Philadelphia paraquat mass tort, and was appointed co-lead counsel in the federal hair-relaxer multidistrict litigation in 2023. She also represents public entities in pending opioid litigation alleging deceptive marketing and over-distribution.

Her work spans state, federal, multidistrict, and coordinated mass-tort proceedings involving toxic exposure and women's health. Each demands the same discipline: common scientific, regulatory, design, warning, and corporate records must remain usable alongside thousands of individual histories. Bellwether trials test that proof in a single case; leadership assignments require the same record to serve many represented people without losing the facts specific to each one.

Background and Practice

After graduating from Canisius College, Fitzpatrick graduated cum laude from American University's Washington College of Law in 1994. She began with gender-discrimination cases, and three years later joined the lawyers who would form Motley Rice, entering state litigation against the tobacco industry — an apprenticeship in tracing corporate knowledge across scientific, regulatory, marketing, and internal records, and presenting that history alongside individual exposure and injury evidence.

Fitzpatrick has said that meeting clients and becoming their voice sustains her when a case becomes difficult. In mass-tort practice, that commitment has a precise meaning: keeping individual histories visible within common discovery, expert analysis, leadership decisions, and trial preparation, so that no client dissolves into a docket number.

Her early gender-discrimination practice still informs a docket centered on women's health — products and reported injuries that may first surface in isolated medical files, dismissed one chart at a time. Fitzpatrick's work brings those reports into a shared evidentiary record while preserving the circumstances of the person who experienced them.